The acquisition of Seagen for $43 billion in 2023 remains key to Pfizer's future growth strategy to mitigate its patent losses and move on from the pandemic era. This purchase significantly expanded its cancer drug portfolio and pipeline.Pfizer has a deep and diverse research and development pipeline with over 100 drug candidates in development, 28 of which are in late-stage trials and include promising programs in oncology and immunology. This is key because the company does face impending patent cliffs on ...